Importantly, myocardial SGLT1 has come under scientific interest [20] as SGLT2 inhibitors (with variable selectivity to SGLT2 over SGLT1) [21,22,23,24] and the dual SGLT1/2 inhibitor sotagliflozin [25] were shown to consistently reduce hospitalization for HF in patients with T2DM, independent of antihyperglycemic or diuretic action [26,27,28]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.